A growing number of studies have found that ZL006 (Figure 1A), a small molecular compound we developed to treat stroke by disrupting PSD-95-nNOS interaction 15, is effective in different preclinical models assessing pain behavior, attenuating both inflammatory and neuropathic pain in rodents 12, 17, 19, 20. Here, DLG4 is linked to Stroke.